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B cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and
Burkitt’s lymphoma (BL) (B-UNC/BL/DLBCL) is a new category of tumors that have features resembling both DLBCL
and BL. These tumors have large and medium sized cells with greater irregularity of nuclei and more prominent
nucleoli than BL. Approximately 35% to 50% have C-MYC rearrangements, although half are non-immunoglobulin
variants. We identified six cases of B-UNC/BL/DLBCL with low-level IGH amplification. Four patients died with a
median survival of 7 months (range, 6–20). In conclusion, to our knowledge low-level IGH amplification has not
been previously described and should be evaluated for in this patient population.
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The 2008 World Health Organization (WHO) Classifica-
tion of Tumours of Haematopoietic and Lymphoid Tis-
sues [1] introduced a new diagnosis called B-cell
lymphoma, unclassifiable, with features intermediate be-
tween diffuse large B-cell lymphoma (DLBCL) and Bur-
kitt’s Lymphoma (BL) (B-UNC/BL/DLBCL). This
diagnosis does not describe a distinct entity, but instead
represents a heterogeneous category that assists in clas-
sifying cases that do not meet the criteria for either clas-
sical BL or DLBCL. Tumors placed in this category
typically consist of either a mixture of large cells resem-
bling DLBCL and smaller cells resembling BL. Also in-
cluded in this category are tumors that morphologically
resemble either BL or DLBCL, but have atypical immu-
nophenotypic and cytogenetic features [1].
We present six cases with this intermediate phenotype
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unless otherwise stated.with immunohistochemistry, conventional cytogenetic
analysis and fluorescence in-situ hybridization (FISH). In
addition to already well defined cytogenetic abnormal-
ities seen in the intermediate phenotype, such as C-
MYC rearrangements and IGH/C-MYC translocations,
these cases each demonstrated low level amplification of
the immunoglobulin heavy chain (IGH) gene. To the
best of our knowledge, IGH amplification has not yet
been reported in patients with B-UNC/BL/DLBCL.Materials and methods
Case selection
A retrospective search covering a 10-year period was
performed using our database software (Sunquest
CoPathPlusTM) with the following key words: ‘Burkitt-
like lymphoma’, ‘atypical Burkitt’s’, ‘high-grade lymphoma’,
‘grey-zone lymphoma’, and ‘B-cell lymphoma, unclassifi-
able’. These cases met the criteria for B-UNC/BL/
DLBCL as defined by the 2008 edition of the WHO
Classification of Tumors of Haematopoietic and Lymph-
oid Tissues [1]. Clinical information was obtained by re-
view of corresponding medical records. A second search
was performed to determine the baseline incidence ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lymphoma.
Tissue sources
Lymph node and/or extranodal tumor biopsies were per-
formed on all patients. Representative formalin-fixed,
paraffin-embedded (FFPE) tissue sections were stained
with routine hematoxylin and eosin (H&E) for morpho-
logic analysis. Additional samples for select cases were
submitted for flow cytometric and cytogenetic analysis,
including FISH when possible. The morphology was
reviewed by a hematopathologist and a diagnosis of B-
UNC/BL/DLBCL was made based on morphologic,
immunophenotypic, and cytogenetic analysis with clin-
ical correlation.
Immunohistochemistry
Immunohistochemical stains were performed on
paraffin-embedded sections of the lymph node and/or
extranodal tumor biopsies using Bond-maX autostainer
(Leica Microsystems, Australia) according to the manu-
facturer’s protocol. Mouse anti-human CD3, CD5,
CD20, CD79a, BCL2, BCL6, Ki-67, and TdT (Ventana
Medical Systems®, Oro Valley, AZ) were used as the pri-
mary antibodies. Horseradish peroxidase-labeled rabbit
anti-mouse polyclonal antibodies were employed to con-
vert the chromogen substrate. All stains were performed
with appropriate positive and negative controls.
Flow cytometric immunophenotyping
Flow cytometric analysis was performed using the
FACSCaliburTM 2000 four-color flow cytometer accord-
ing to the standard protocol (Becton Dickinson, San
Jose, CA). Directly conjugated monoclonal antibodies
(Becton Dickinson, San Jose, CA) to the following anti-
gens were used for this analysis: CD2, CD3, CD4, CD5,
CD7, CD8, CD10, CD19, CD20, CD23, CD38, CD45,
CD79a, BCL2, FMC7, HLA-DR, and terminal deoxynu-
cleotidyl transferase (TdT). Polyclonal and monoclonal
rabbit anti-human immunoglobulin light chains were
obtained (Becton Dickinson, San Jose, CA). All anti-
bodies were conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), allophycocyanin (APC), or
PerCP-Cy5.5. The flow cytometric data was analyzed
using CellQuest software (Becton-Dickinson, San Jose,
CA).
Cytogenetic studies
Conventional G-banded cytogenetic analysis on 20 meta-
phase spreads was performed on two cases of tumor tis-
sue and one case of lymph node tissue using methods
previously described. The karyotypes were reported ac-
cording to the 2013 International System for Human
Cytogenetic Nomenclature [2]. FISH analysis of 100 to200 nuclei was performed on fresh tumor or lymph node
tissue and/or FFPE tissue sections as previously de-
scribed [3], using the following probes: LSI IGH(14q32)/
BCL2(18q21) Dual Color and LSI IGH(14q32/ MYC
(8q24)/CEP 8 Tri-Color Dual Fusion (DF) probes; and
LSI MYC(8q24) Dual Color, LSI IGH(14q32) Dual Color,
LSI BCL2(18q21) Dual Color, and LSI TCR-alpha/delta
(14q11.2) Dual Color Break Apart Rearrangement (BAR)
probes. All probes were supplied by Abbot Molecular
(Des Plaines, IL). Low-level amplification was defined as
three to six copies of a gene locus.
Results
Clinical findings
During the 10-year search period, we identified six cases
that met the 2008 WHO criteria for B-UNC/BL/DLBCL
[1]. During the same period, FISH for IGH was per-
formed on 146 cases of lymphoma and among these,
only the six cases of B-UNC/BL/DLBCL showed three
or more copies of the IGH locus. The clinical data for
these six patients is summarized in Table 1. There were
four males and two females with a median age of 54
(range, 4–68). Four patients (cases 2, 3, 5 and 6) pre-
sented with extranodal tumors. At presentation, none of
the patients had hepatosplenomegaly. Lymphadenopathy
was detected in four patients (cases 1, 2, 4 and 6). An el-
evated LDH level was detected in all patients at presen-
tation, ranging from 265 to 978 U/l, with a median of
750 U/l (normal range: 94–250 U/l). The median leukocyte
count at presentation was 8.25 × 109/l, ranging from
3.6 to 11.4 × 109/l (normal range: 4.8 to 10.8 × 109/l).
None of the patients presented with central nervous
system (CNS) involvement. During the course of disease
in two patients (cases 5 and 6), intracerebral lesions
were found by computerized tomography (CT) scanning
and lymphoma cells were detected in cerebrospinal fluid
analysis. Bone marrow and peripheral blood involve-
ment were detected in one patient (case 5) during the
course of disease. All patients were treated with inten-
sive chemotherapy regimens (IC) supplemented with
rituximab. Three patients (cases 2, 3, and 6) underwent
autologous hematopoietic stem cell transplant (HSCT)
for treatment of relapses. One patient (case 5) under-
went external beam radiation therapy of an extranodal
tumor. Four patients (cases 1, 2, 5, and 6) died with a
median survival of 7 months (range, 6–20) after pro-
gressing to disseminated disease. Two patients (cases 3
and 4) are alive at 105 and 42 months after diagnosis,
respectively, at this time, with the former experiencing
multiple relapses.
Morphologic and immunophenotypic findings
Morphologic and immunophenotypic data for all six pa-
tients are summarized in Table 1. At low power
Table 1 Summary of clinical, immunophenotypic, and cytogenetic data for all six patients
Case # Age/Gender Involved sites at presentation Immunophenotype Karyotype1 FISH2 (% cells) Therapy3 Outcome/Follow up
Nodal Extranodal BCL2 BCL6 CD10 CD38 MUM1 sIg Ki-67%
1 52/M Paraaortic, pancreatic,
portohepatic, cervical,
axillary, mediastinal
NA + + - NA NA λ 100 Complex4 IGH x 3 (100%) IC DIED/8 Months
2 24/M Left external iliac Left femoral neck + + + NA + - 75-80 46,XY IGH/C-MYC (46%),
IGH x 3–4 (51%)
IC, HSCT DIED/20 Months
3 61/F NA Left maxillary sinus + + - NA + κ 100 46,XX IGH x 3 (20%) IC, HSCT ALIVE/105 Months
(Multiple Relapses)
4 68/F Gastrohepatic, periaortic,
pericaval, mesenteric
NA + + + + NA κ 95-99 NA IGH/BCL2 (91.5%),
C-MYC x 3–4 (87%),
IGH x 3 (42%)
IC ALIVE/42 Months
5 44/M NA Right submandibular
space, right lateral neck
+ + + + NA κ 100 NA IGH/C-MYC,
C-MYC x 3–4, IGH x 3–6,
BCL2 x 3–6 (96%)
IC, EBRT DIED/6 Months
6 4/M Retroperitoneal,
mesenteric
Liver, Omentum + + + + NA κ 95-99 NA C-MYC x 3 (13%),
IGH x 3 (17%)
IC, HSCT DIED/6 Months
1Karyotype: standard cytogenetic evaluation performed using G-banding.
2FISH: performed using the following Abbott Molecular (Des Plaines, Ill) probes: LSI IGH(14q32)/BCL2(18q21) Dual Color, LSI IGH(14q32)/MYC(8q24)/CEP8 Tri-Color Dual Fusion, LSI MYC Dual Color Break Apart (8q24),
LSI IGH Dual Color Break Apart (14q32), and LSI TCR alpha/delta Dual Color Break Apart (14q11.2) probes.
3Therapy: IC, Intensive chemotherapy; HSCT, Hematopoietic Stem Cell Transplant; EBRT, External Beam Radiotherapy.
4Complex Karyotype for patient 1: 44,X,-Y,add(3)t(3;22)(p25;q12),t(8;14)(q24;q32),-21.
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Figure 1 Morphologic and immunophenotypic findings. (A) A pelvic mass core biopsy from case 4 showing sheets of medium to large sized
abnormal lymphoid cells in a diffuse growth pattern. There is a monotonous appearance to the proliferating cells. A starry-sky pattern with
tingible-body macrophages is seen (Hematoxylin-Eosin, original magnification × 400). (B) BCL-2 immunohistochemistry from the same case
showing diffuse membranous and cytoplasmic staining of tumor cells (original magnification × 200).
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pattern with complete effacement of normal lymphoid
architecture. Each case also showed a high mitotic rate
and a “starry sky” pattern. At higher power magnifica-
tion, each case was composed of a monomorphic popu-
lation of medium sized cells admixed with finely
dispersed nuclear chromatin and inconspicuous nucleoli
(Figure 1A). Each case also featured a smaller population
of larger centroblastic cells. Necrosis was only seen in
case 6. The proliferation index, estimated via Ki-67 im-
munohistochemical staining, was 75 to 80% in case 2
and greater than 95% in all other cases. Monotypic sur-
face immunoglobulin light chain expression was de-
tected in five cases (κ 4 and λ 1). All cases expressed
BCL-2 (Figure 1B) and BCL-6. CD10 expression was de-
tected in four cases.
Cytogenetic findings
Cytogenetic data for all six patients are summarized in
Table 1. A karyotype was available in only cases 1, 2, andFigure 2 Cytogenetic findings. (A) Interphase nuclear FISH from Case 5 u
probe (Abbott Molecular Des Plaines, Il) demonstrates amplification of IGH
LSI IGH(14q32)/MYC(8q24)/Cep8(p11-q11) Tri Color Dual Fusion (DF) probe
(green), a t(8:14)(q24;q32) (red and yellow) and a normal signal pattern for
FISH from Case 4 using the same DF probe demonstrates amplification of
8p11-q11 region of chromosome 8 (aqua).3. One patient (case 1) had a complex karyotype (44,X,-
Y,add(3)t(3;22)(p25;q12),t(8;14)(q24;q32),-21) and the
other two were normal. FISH analysis was performed on
fresh (cases 1, 2, 3, and 4) and FFPE (cases 1, 2, 3, 5 and
6) tissue. Each patient had three to six copies of IGH
(Figure 2A-C), three patients (cases 4, 5, 6) had three to
four copies of C-MYC (Figure 2C) and one patient (case
5) had three to six copies of BCL2. One patient (case 4)
had an IGH/BCL2 translocation and two patients (cases
2 and 5) had an IGH/C-MYC translocation (Figure 2B).
All patients had normal signal patterns for the TCR-
alpha/delta and CEP8 loci.
Discussion
B-UNC/BL/DLBCL represents a heterogeneous group of
high grade B-cell lymphomas that cannot be adequately
classified as either BL or DLBCL [1]. Cases within this
spectrum exhibit features of BL and DLBCL, thus mak-
ing it difficult to discriminate one from another. In this
retrospective study, low-level IGH amplification wassing the LSI IGH(14q32) Dual Color Break Apart Rearrangement (BAR)
(four fusion signals). (B) Interphase nuclear FISH from Case 5 using the
(Abbott Molecular Des Plaines, Il) demonstrates amplification of IGH
the 8p11-q11 region of chromosome 8 (aqua). (C) Interphase nuclear
both IGH (green) and MYC (red) and a normal signal pattern for the
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To the best of our knowledge, this is the first time low-
level IGH amplification has been described in association
with B-UNC/BL/DLBCL. This novel finding may provide
new insight in better classifying these “grey zone” cases.
The morphologic characteristics of B-UNC/BL/DLBCL
include features of both BL and DLBCL [1]. Mono-
morphic medium-sized cells resembling those seen in
BL tend to be the predominant cell type in most cases
and they are typically associated with a high proliferation
rate and a starry-sky pattern. Each case also features a
variable amount of larger cells that exhibit nuclear
pleomorphism, open vesicular chromatin and multiple
nucleoli; all which is more typical of DLBCL. This
morphologic heterogeneity was very evident in each
case reported in this series. It is one feature that distin-
guishes intermediate cases from classic BL (Figure 1). The
immunophenotype of B-UNC/BL/DLBCL also tends to be
variable, expressing germinal center markers such as
CD10 and BCL6, but often also expressing BCL2 and typ-
ically have a Ki-67 proliferation index (PI) varying between
50% and 95% [1]. Consistent with this, all our cases
expressed BCL2 and at least one germinal center marker;
five cases expressed at least one post-germinal center
marker (i.e. CD38, MUM1) and only one case had a PI
less than 95% (Table 1).
To our knowledge, this study is the first to document
the presence of IGH amplification in association with B-
UNC/BL/DLBCL. Low-level amplification of other genes
such as C-MYC, BCL2, and BCL6, has been described.
Foot et al. [4] studied 160 cases of non-Burkitt high
grade B-cell non-Hodgkin’s lymphoma and found nu-
merous cytogenetic abnormalities by FISH. Three to six
copies of C-MYC, BCL2, and BCL6 were detected in
19%, 28%, and 22% of cases, respectively. Kodet et al. [5]
re-evaluated 39 cases of previously diagnosed BL or
Burkitt-like lymphoma using IHC and FISH. Cytogenetic
finding in four cases that were reclassified as B-UNC/
BL/DLBCL included a break in the IGH locus and high-
level C-MYC amplification. A recent study of 39 cases of
B-UNC/BL/DLBCL by Perry et al. [6] found amplifica-
tion of C-MYC, BCL2, or BCL6 in fourteen cases, either
alone or in addition to other cytogenetic findings. Im-
portantly, although each study [4-6] utilized Dual Fusion
and/or Break Apart probes specific for IGH, no case
with three or more copies was identified.
Three cases in this series also showed low-level C-MYC
amplification. B-UNC/BL/DLBCL associated with C-MYC
amplification but without IGH/C-MYC translocation or
any of its variants is associated with a poor prognosis
[7]. Low-level C-MYC amplification in conjunction with
BCL2 rearrangements in cases of B-UNC/BL/DLBCL
has been previously described [4,6]. Since C-MYC rear-
rangements occur in 10% of patients with DLBCL, theirpresence does not change the diagnosis to B-UNC/BL/
DLBCL [8]. Similarly, this diagnosis should not be made
in cases of otherwise typical BL that lack a detectable
C-MYC rearrangement. C-MYC translocations to loci
other than an immunoglobulin gene are rarely seen in
typical cases of BL, but account for up to half of the
C-MYC rearrangements seen in B-UNC/BL/DLBCL
[1]. Three cases in our series featured C-MYC rearrange-
ments that were translocated to IGH.
Anywhere from 35 to 50% of B-UNC/BL/DLBCL cases
have C-MYC translocations and about 15% of these are
accompanied by either BCL2 or BCL6 rearrangements.
These “double-hit” lymphomas are among the best char-
acterized subset of B-UNC/BL/DLBCL and carry a poor
prognosis [1,9]. Li et al. [10] suggest that either C-MYC
rearrangement and BCL2 amplification or BCL2 re-
arrangement and C-MYC amplification should also be
classified as “double hit” since in their series such cases
showed poor outcomes similar to cases with both genes
rearranged. However, in our series, similar to Perry et al.
[6], a patient with C-MYC rearrangement accompanied
by BCL2 amplification showed longer survival (case 4,
42 months) than a patient with BCL2 rearrangement
and C-MYC amplification (case 5, 6 months). Further
study is necessary to determine how these different
mechanisms of C-MYC and BCL2 dysregulation influ-
ence survival of patients with B-UNC/BL/DLBCL.
Over half of patients with B-UNC/BL/DLBCL present
with widespread, often extra-nodal disease. In contrast
with BL, these tumors do not show any preferential
localization in particular sites, such as the ileocecal re-
gion or jaws. Marrow and CNS involvement are not un-
common. B-UNC/BL/DLBCL follows an aggressive
course and no appropriate therapeutic approach has
been established. The prognosis in our case series was
poor since four of six patients in our series died within
six to 20 months of initial diagnosis. In a recent study
[5], clinical features such as gender, age, and stage were
not statistically different between patients who died
within four years of diagnosis and those who were alive
at four years. In our series, each deceased patient was
younger than 55 years of age and progressed to dissemi-
nated disease despite receiving multiple cycles of IC reg-
imens. Furthermore, of the three patients who received a
HSCT, two died. Studies have shown poor outcomes in
patients with B-UNC/BL/DLBCL irrespective of stand-
ard DLBCL therapy (i.e. R-CHOP) or a more aggressive
approach (i.e. IC regimens or HSCT) [5,11]. One of the
surviving patients in our series experienced a relapse five
years after diagnosis that was treated with HSCT.
Conclusions
In conclusion, IGH amplification is a previously undescribed
cytogenetic abnormality in patients with B-UNC/BL/
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to be poor and this was confirmed in most of our pa-
tients. Interestingly, the patient with the longest sur-
vival was found to have low-level IGH amplification as
its only cytogenetic abnormality. The prognostic sig-
nificance of low-level amplification of other gene loci
such as C-MYC, BCL2, and BCL6 remains uncertain
[6]. Therefore, further study is needed to investigate
the predictive role of low-level amplification of IGH
and other genes in patients with B-UNC/BL/DLBCL.
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